Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: EPICOVIDEHA-EPIFLUEHA Report

Jon Salmanton-García*, Francesco Marchesi, Milan Navrátil, Klára Piukovics, Maria Ilaria del Principe, Marianna Criscuolo, Yavuz M. Bilgin, Nicola S. Fracchiolla, Antonio Vena, Alessandra Romano, Iker Falces-Romero, Nicola Sgherza, Inmaculada Heras-Fernando, Monika M. Biernat, Verena Petzer, Pavel Žák, Barbora Weinbergerová, Michail Samarkos, Nurettin Erben, Jens van PraetAlberto López-García, Jorge Labrador, Tobias Lahmer, Ľuboš Drgoňa, Maria Merelli, Annarosa Cuccaro, Sonia Martín-Pérez, Julio Dávila-Valls, Francesca Farina, Chiara Cattaneo, László Imre Pinczés, Ferenc Magyari, Ildefonso Espigado, Caterina Buquicchio, Donald C. Vinh, Igor Stoma, Martin Čerňan, Lucia Prezioso, Mario Virgilio Papa, Gaëtan Plantefeve, Reham Abdelaziz Khedr, Josip Batinić, Gabriele Magliano, Simge Erdem, Sofya Khostelidi, Natasha Čolović, Davide Nappi, Patricia García-Ramírez, Jakub Góra, Martijn Bakker, Oliver A Cornely, Livio Pagano*

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    Abstract

    Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA-EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023–2024 autumn–winter season. The study assessed epidemiology, clinical characteristics, risk factors, and outcomes. The study examined 1312 patients with HM diagnosed with CARV during the 2023–2024 autumn–winter season. Of these, 59.5% required hospitalization, with 13.5% needing ICU admission. The overall mortality rate was 10.6%, varying by virus: parainfluenza (21.3%), influenza (8.8%), metapneumovirus (7.1%), RSV (5.9%), or SARS-CoV-2 (5.0%). Poor outcomes were significantly associated with smoking history, severe lymphopenia, secondary bacterial infections, and ICU admission. This study highlights the severe risk CARV poses to patients with HM, especially those undergoing active treatment. The high rates of hospitalization and mortality stress the need for better prevention, early diagnosis, and targeted therapies. Given the severe outcomes with certain viruses like parainfluenza, tailored strategies are crucial to improving patient outcomes in future CARV seasons.

    Original languageEnglish
    JournalAmerican Journal of Hematology
    DOIs
    Publication statusE-pub ahead of print - 23-Dec-2024

    Keywords

    • antiviral therapy
    • community-acquired respiratory viral infection
    • hematological malignancy
    • secondary infection
    • vaccine coverage

    Fingerprint

    Dive into the research topics of 'Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: EPICOVIDEHA-EPIFLUEHA Report'. Together they form a unique fingerprint.

    Cite this